Ipidacrine

Ipidacrine is a small molecule drug classified as a reversible acetylcholinesterase inhibitor and is used primarily for the treatment of memory disorders of various origins and myasthenia gravis. It was first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation as a modification of tacrine. Ipidacrine acts through two main mechanisms: it reversibly inhibits cholinesterase (both acetylcholinesterase and butyrylcholinesterase) in synapses to increase acetylcholine levels and blocks neuronal membrane potassium channels to directly stimulate impulse transmission in both central and peripheral nervous systems. Additionally, it enhances the effects of other neurotransmitters such as adrenaline (epinephrine), serotonin, histamine, and oxytocin on smooth muscle. Clinically it has been used for cognitive impairment (including Alzheimer's disease), myasthenia gravis, vascular encephalopathy/stroke recovery support, peripheral neuropathies (including diabetic neuropathy), focal neuropathies of upper extremities and alcoholic neuropathies[1][3][5][6][7][8].

Brand names

NeiromidinAxamonIpidacrine GrindeksIpigriksIpigrixNeuromidin

Other names

amiridineipidacrinumipidacrinipidacrina2,3,5,6,7,8-Hexahydro-H-cyclopenta[b]quinolin-9-amine9-amino-2,3,5,6,7,8-Hexahydro-H-cyclopenta[b]quinoline